Abstract
O n September 27, 1978, the director of a major government research institute called for an extraordinary experiment. Arthur C. Upton, head of the National Cancer Institute (NCI), approved a clinical trial for the controversial anti-cancer drug, Laetrile. The uninformed reader might well interpret this decision as a routine health policy judgment based upon the usual clinical criteria for testing potential anti-tumor agents. Some background is necessary to correct this misapprehension and thus assure a proper appreciation of the broadened perspectives that have encouraged NCI to move beyond the limits of traditional medical research.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
